Posted by Michael Wonder on 07 Mar 2018
EMA recommends immediate suspension and recall of multiple sclerosis medicine Zinbryta
7 March 2018 - Evidence indicates risk of serious inflammatory brain disorders.
The EMA has recommended the immediate suspension and recall of the multiple sclerosis medicine Zinbryta (daclizumab beta) following 12 reports of serious inflammatory brain disorders worldwide, including encephalitis and meningoencephalitis. Three of the cases were fatal.
A preliminary review of the available evidence indicates that immune reactions observed in the reported cases may be linked to the use of Zinbryta. Zinbryta may also be linked to severe immune reactions affecting several other organs.
